
Amgen jumps after teasing weight-loss drug data, rival stocks fall
By Manas Mishra and Christy Santhosh (Reuters) -Amgen shares headed for their best session since 2009 on Friday after the U.S. drugmaker hinted at encouraging interim trial data on its experimental obesity drug, denting rival stocks but leaving analysts frustrated with a lack of details. Weight-loss drugmaker Eli Lilly’s shares fell 1.6% while Novo Nordisk’s…